ProCE Banner Activity

How I Adapt CLL Treatment to Evolving Molecular Considerations

Clinical Thought
How should factors such as del(17q) and IgHV mutations be leveraged to individualize treatment in CLL?

Released: August 09, 2016

Expiration: August 08, 2017

No longer available for credit.

Share

Faculty

Andrew D. Zelenetz

Andrew D. Zelenetz, MD, PhD

Associate Professor, Department of Medicine
Cornell University Medical College
Chief, Lymphoma Service
Memorial Sloan-Kettering Cancer Center
New York, New York

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

Genentech Roche Virology

Janssen Pharmacyclics

Pharmacyclics Inc

Faculty Disclosure

Primary Author

Andrew D. Zelenetz, MD, PhD

Associate Professor, Department of Medicine
Cornell University Medical College
Chief, Lymphoma Service
Memorial Sloan-Kettering Cancer Center
New York, New York

Andrew D. Zelenetz, MD, PhD, has disclosed that he has received consulting fees from Adaptive Biotechnology, Amgen, Celgene, Genentech/Roche, Gilead Sciences, GlaxoSmithKline, Hospira, Janssen, Nanostring Technologies, Novartis, Portola Pharmaceuticals, and Takeda Pharma; has received funds for research support from Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Janssen, and Roche; and has served on the data monitoring committee for Boehringer Ingelheim.